Intratect (Human Normal Immunoglobulin)

Human normal immunoglobulin contains a broad spectrum of IgG antibodies pooled from thousands of donors. These antibodies bind to pathogens, neutralizing them, and also interact with immune cells via Fc receptors, inhibiting complement activation and reducing inflammatory processes. By supplementing the patient’s own antibody pool, it restores humoral immunity and helps regulate abnormal immune activity.

The dosage of Intratect is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and therapeutic goals. Typically, dosing regimens are calculated in grams of IgG per kilogram of body weight and administered over several hours. Exact dosing schedules, infusion rates, and treatment intervals should be determined by a qualified healthcare professional.

Safety data for Intratect in pregnancy and lactation are limited, and the product is classified with an unknown pregnancy category. Use during pregnancy or while breastfeeding should only be considered when the potential benefits outweigh any potential risks to the mother or infant. Clinicians should evaluate each case carefully and discuss possible implications with the patient.

To request Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with import documentation.

Intratect is a pooled human IgG solution comparable to other intravenous immunoglobulin (IVIG) preparations in its composition of broad‑spectrum antibodies. Differences among IVIG products may include manufacturing processes, stabilizers, and specific IgG subclass distributions, which can influence infusion tolerability and pharmacokinetics. Clinicians select a product based on patient response, safety profile, and logistical considerations such as supply chain reliability.

Intratect must be stored refrigerated at 2 °C to 8 °C. The vials should be kept in their original packaging to protect from light, and they must not be frozen or shaken. Prior to administration, allow the product to reach room temperature if recommended by the manufacturer, and inspect for any particulate matter or discoloration before use.

Intratect is given as an intravenous infusion. The solution is diluted according to the manufacturer’s instructions and infused slowly, typically over several hours, especially during the first administration to monitor for infusion‑related reactions. Infusion rates may be increased gradually if the patient tolerates the initial dose, and the procedure should be performed by trained healthcare personnel in a setting equipped for emergency management.

Serious adverse events linked to Intratect include anaphylactic or severe allergic reactions, thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, acute renal failure, aseptic meningitis, and hemolytic anemia. Patients should be closely monitored during and after infusion for signs of these conditions, and immediate medical attention is required if severe symptoms develop.

Intratect is contraindicated in individuals with a known hypersensitivity to human immunoglobulin preparations or any of the product’s excipients. Patients with uncontrolled hypercoagulable states, severe renal impairment, or a history of severe adverse reactions to IVIG should avoid its use unless a specialist determines that benefits outweigh risks. Clinical judgment is essential to identify unsuitable candidates.